Morgan Stanley analyst Joshua Pokrzywinski maintained a Hold rating on Flowserve (FLS – Research Report) today and set a price target of $35.00. The company’s shares closed last Friday at $31.83.
According to TipRanks.com, Pokrzywinski is a 5-star analyst with an average return of 11.0% and a 65.2% success rate. Pokrzywinski covers the Industrial Goods sector, focusing on stocks such as Advanced Drainage Systems, Honeywell International, and Lennox International.
The word on The Street in general, suggests a Hold analyst consensus rating for Flowserve with a $36.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Flowserve’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $866 million and net profit of $49.79 million. In comparison, last year the company earned revenue of $924 million and had a net profit of $56.12 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flowserve Corp. engages in the manufacture and provision of aftermarket service for comprehensive flow control systems. It operates through the following segments: Flowserve Pump Division and Flow Control Division. The Flowserve Pump Division segment provides pumps, pre-configured industrial pumps, pump systems, mechanical seals, auxiliary systems and replacement parts and related services. The Flow Control Division segment involves engineered and industrial valves, control valves, actuators and controls and related services. The company was founded in 1790 and is headquartered in Irving, TX.
Read More on FLS:
- Cytokinetics (CYTK) Received its Third Buy in a Row
- Morgan Stanley Maintains a Hold Rating on Brinker International (EAT)
- RBC Capital Keeps a Buy Rating on JPMorgan Chase & Co. (JPM)
- JPMorgan Chase & Co. (JPM) Gets a Buy Rating from Goldman Sachs
- In Search of a Better Covid Vaccine, This Analyst Taps Ocugen
